16:38 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Boehringer, Lilly's Tradjenta meets in first CV outcomes trial

Boehringer Ingelheim GmbH (Ingelheim, Germany) and partner Eli Lilly and Co. (NYSE:LLY) said Tradjenta linagliptin met the primary endpoint of improving time to first occurrence of a major cardiovascular event (MACE), including CV death, non-fatal...
08:00 , Feb 11, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Downstream regulatory element antagonistic modulator (DREAM); ATP-dependent potassium channel (KATP)

Neurology INDICATION: Huntington's disease (HD) In vitro, patient sample and mouse studies suggest inhibiting DREAM with NovoNorm repaglinide could help treat HD. Striatal levels of DREAM were lower in postmortem brain tissue samples from patients...
07:00 , May 21, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: ATP-dependent potassium channel (KATP)

Neurology INDICATION: Alzheimer's disease (AD) Mouse studies suggest KATP agonists could help prevent AD in patients with Type II diabetes or other forms of hyperglycemia, which increases the risk of AD. In mouse models of...
07:00 , Apr 6, 2015 |  BC Week In Review  |  Clinical News

Diazoxide choline controlled release: Phase I data

The open-label first part of the 2-part, U.S. Phase I PC025 trial in 13 obese Prader-Willi patients ages 10-22 showed that oral DCCR for 10 weeks significantly reduced body fat by 4.2% (p=0.003), reduced hyperphagia...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Clinical News

Diazoxide choline controlled release: Phase I started

Essentialis began the 2-part, U.S. Phase I PC025 trial of oral DCCR in 12 obese Prader-Willi patients ages 10-20 years. In the open-label first part, patients will receive a starting dose of 1.5 mg/kg DCCR,...
07:00 , Jun 23, 2014 |  BC Week In Review  |  Clinical News

Diazoxide choline controlled release regulatory update

FDA granted Orphan Drug designation to Essentialis’ diazoxide choline controlled release (DCCR) to treat Prader-Willi syndrome. The ATP-dependent potassium channel (KATP) agonist is in Phase I testing for the indication, with data expected in 3Q14....
07:00 , Jun 5, 2014 |  BC Innovations  |  Strategy

Sanford-Burnham goes fourth

Sanford-Burnham Medical Research Institute 's outreach to industry has resulted historically in deals focused either on a narrow range of projects or the work of individual investigators, but the institute also has been seeking broader...
07:00 , Jul 1, 2013 |  BioCentury  |  Product Development

POC for APOCIIIRx

If initial Phase II data bear out in larger trials, Isis Pharmaceuticals Inc. thinks ISIS-APOCIIIRx could alter the treatment landscape for hypertriglyceridemia much like statins did for hypercholesterolemia. ISIS-APOCIIIRx is an antisense inhibitor of apolipoprotein...
07:00 , Mar 18, 2013 |  BioCentury  |  Emerging Company Profile

gIcare: Colonoscopy comfort

gIcare pharma Inc. is developing a pipeline of non-sedating colonic analgesic compounds to provide new and lower cost alternatives for pain management during colonoscopy. Sedation during endoscopy has become routine practice among gastroenterologists, even though...
08:00 , Mar 5, 2012 |  BC Week In Review  |  Clinical News

Diazoxide choline controlled release: Phase IIb data

Essentialis reported data from a double-blind Phase IIb trial in 44 non-diabetics with fasting triglyceride levels of >=500 mg/dL evaluating DCCR in combination with a statin or with fenofibrate. In combination with Lipitor atorvastatin, DCCR...